Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in corticosteroids.

Günther Hochhaus1

  • 1Department of Pharmaceutics, College of Pharmacy, University of Florida, Box 100494, Gainesville, FL 32610, USA. Hochhaus@UFL.edu

Proceedings of the American Thoracic Society
|August 23, 2005
PubMed
Summary

Optimizing inhaled corticosteroid therapy requires enhanced drug delivery to the lungs. Future research focuses on improving deposition, reducing side effects, and increasing treatment effectiveness through advanced formulations and delivery systems.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensitivity of Pharmacokinetics to Differences in the Particle Size Distribution for Formulations of Locally Acting Mometasone Furoate Suspension-Based Nasal Sprays.

Molecular pharmaceutics·2023
Same author

Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics.

Pharmaceutical research·2023
Same author

Mechanistic modeling of generic orally inhaled drug products: A workshop summary report.

CPT: pharmacometrics & systems pharmacology·2022
Same author

Correction to: Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?

The AAPS journal·2021
Same author

Optimization of the Transwell<sup>®</sup> System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches.

Pharmaceutics·2021
Same author

Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?

The AAPS journal·2021

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Inhaled corticosteroid (ICS) therapy aims for targeted lung delivery to maximize pulmonary effects and minimize systemic side effects.
  • Current ICS delivery faces challenges in achieving optimal drug concentration and residence time within the lungs.
  • Pharmacokinetic and pharmacodynamic assessments highlight key characteristics for ideal ICS therapy.

Purpose of the Study:

  • To outline the ideal characteristics of inhaled corticosteroids and their delivery systems for effective pulmonary therapy.
  • To identify future research and development directions for improving ICS efficacy and safety.
  • To guide the design of next-generation ICS treatments.

Main Methods:

  • Review of pharmacokinetic/pharmacodynamic principles for pulmonary drug delivery.
  • Analysis of ideal attributes for ICS drugs and delivery devices.
  • Identification of emerging technologies and strategies for enhanced ICS therapy.

Main Results:

  • Ideal ICS therapy requires high pulmonary deposition efficiency and low oral bioavailability.
  • Optimized pulmonary residence time and high systemic clearance are crucial for efficacy and safety.
  • Selective binding to the glucocorticoid receptor is a key pharmacodynamic target.

Conclusions:

  • Future ICS development should prioritize improved delivery devices for higher lung deposition.
  • Novel drug formulations (liposomes, microspheres, nanocoatings) and biological systems are needed for prolonged pulmonary residence time.
  • Development of soft drugs with efficient systemic clearance and enhanced pharmacodynamic selectivity will improve ICS therapy.

Related Experiment Videos